Wider use of breast cancer drug urged after ‘unprecedented’ benefits
Patients with a type of breast cancer known as HER2 positive — which makes up about a quarter of all breast cancers — who were given Perjeta on top of older medicine Herceptin and chemotherapy, lived 15.7 months longer than those on Herceptin and chemotherapy alone.
That is the longest extension to survival ever seen for a drug studied in metastatic breast cancer, where disease has spread to other parts of the body.
